Blocking CD14 antibodies, such as the human anti-CD14 antibody IC14 (Axtelle and Pribble, 2001), could represent an alternative way to treat recurring infections caused by type 1 piliiated pathogens, such as UTIs or inflammatory bowel diseases like Crohn’s disease (Sivignon et al., 2017), given that CD14 is expressed by hematopoietic but also non-hematopoietic cells (Zanoni and Granucci, 2013). Here, CD14 is linked to inflammatory bowel disease.